Diethylcarbamazine Dosing for Tropical Pulmonary Eosinophilia

Standard Treatment Regimen

The UK guidelines recommend diethylcarbamazine (DEC) 6 mg/kg/day divided into 3 doses for 14 days for tropical pulmonary eosinophilia (TPE) 1, 2
Adding doxycycline 200 mg daily for 6 weeks to target the symbiotic Wolbachia bacteria is recommended for TPE treatment 1, 2
Extending DEC treatment to 21 days may be more effective, particularly for chronic cases, as this duration has been the traditional standard and may reduce relapse rates 3, 4

Before initiating DEC therapy, it is essential to exclude co-infections that can cause life-threatening complications, such as onchocerciasis and loiasis 1, 2, 5
Screening for onchocerciasis via skin snips and slit lamp examination, or giving a test dose of DEC 50 mg to detect co-infection, is recommended 1, 2, 5
Screening for loiasis with daytime blood microscopy (10 am-2 pm) is necessary if the patient has traveled to endemic regions in Central/West Africa 1, 5, 6
DEC is absolutely contraindicated in patients with onchocerciasis or high-load loiasis (>1000 microfilariae/ml) due to the risk of blindness and fatal encephalopathy 5, 6, 7

TPE typically presents with fever, dry cough, wheeze, and breathlessness, often misdiagnosed as asthma 3, 4
Marked eosinophilia (typically >3 × 10⁹/L) is a characteristic feature of TPE 3, 4
Strongly positive filarial serology with negative blood microfilariae is a common finding in TPE patients 3, 4
Chest X-ray showing interstitial shadowing or reticulonodular infiltrates in 80% of cases is a typical radiological feature of TPE 3, 4

Consider adding corticosteroids (e.g., prednisolone 20 mg/day for 5 days initially, with longer courses for chronic cases) if patients fail to respond adequately or relapse after DEC 1
Re-treatment is necessary in approximately 20% of cases, and repeat or extended DEC treatment for additional cycles may be required 3, 4

The American College of Obstetricians and Gynecologists and other guideline societies recommend avoiding DEC in pregnancy and seeking expert consultation 5, 7
The use of DEC during breastfeeding is limited, and expert consultation is recommended 5, 7
For children 12-24 months, discussion with an expert before treatment is necessary 5, 7

DEC should be taken with food to improve tolerability 5
Monitoring for adverse reactions, including fever, lymphadenitis, and allergic reactions, is essential during DEC treatment 5, 7

Diethylcarbamazine (DEC) 6 mg/kg/day divided into three doses for 14–21 days is the definitive first‑line therapy for tropical pulmonary eosinophilia, provided onchocerciasis and loiasis co‑infection have been excluded. 8, 9

Patients typically experience rapid resolution of fever, cough, wheeze, and breathlessness after initiating DEC. 8, 9

Relapse occurs in approximately 20 % of treated individuals, necessitating a second identical course of DEC. 8, 9
The second course uses the same dosing regimen (6 mg/kg/day in three divided doses). 8

Inadequate or delayed treatment can lead to irreversible pulmonary fibrosis, chronic interstitial lung disease, and persistent restrictive lung function or pulmonary hypertension. 8, 9

Typical presentation includes fever, dry cough, wheeze, and dyspnea, frequently misdiagnosed as asthma. 8, 9
Peripheral eosinophil count is usually > 3 × 10⁹ L (≈ 3000 cells/mm³). 8, 9
Serum IgE levels are often > 1000 IU/mL. 8, 9
Filarial serology is strongly positive while peripheral blood microfilariae are absent. 8, 9
Chest radiography shows interstitial shadowing, reticulonodular or miliary infiltrates in ~80 % of cases (normal in ~20 %). 8, 9
Pulmonary function testing reveals an obstructive pattern early in disease and a restrictive pattern in later stages. 8, 9